http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010014248-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19d3b813fb9e53bd4e250afa1a3ebcca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_498c4e720477cfd631eeaa8ad2cba3c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2572a9a9928025077f5d9aba781d62f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc3855697c66df235ed0ce4930ca73cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f3c963243884e5caf7584d341e4d413
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
filingDate 2009-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f480f768b90520aa3faef22ac42df3d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d487d7815410970cb0843e500f66545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4be253dafc24f98d36669742ee636ffb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05f372e5d8a0f29a15bc82020b6ccf0
publicationDate 2010-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2010014248-A3
titleOfInvention Antiviral activity of the protein scytovirin and methods of use
abstract The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The instant invention describes novel methods for treating viral infections, in particular infections caused by high mannose enveloped viruses, for example hepatitis C virus (HCV).
priorityDate 2008-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03097814-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006127822-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005084496-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID11103
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86041
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID11103
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581501
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID161658
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405416

Total number of triples: 34.